Sunshine Biopharma Launches NIOPEG(R) Into $10B Biologics Market

Sunshine Biopharma Inc. (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched NIOPEG, the Company's first Biosimilar drug on the market.

NIOPEG is a Biosimilar comparable to the reference biologic drug NEULASTA (Pegfilgrastim). Like NEULASTA, NIOPEG is a long-acting, pegylated form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving chemotherapy. NIOPEG is available in a prefilled syringe of 6mg/0.6mL.

As of 2024, the global market size for NEULASTA and its biosimilars was estimated at $4.5B, with projections suggesting it could reach $9.2B by 2033, growing at a compound annual growth rate (CAGR) of 8.5% (Verified Market Reports). The growth is largely driven by rising global cancer incidence and chemotherapy use.

The Canadian market for NEULASTA and its Biosimilars is smaller but still significant due to high biologics spending. Biologic drug sales in Canada reached $10B in 2020, accounting for about one-third of total pharmaceutical spending (www.canada.ca). NEULASTA is one of the key biologics used in oncology, and its biosimilars have been gaining traction, especially after provincial switching policies were introduced to encourage cost savings.

Although Canada represents a smaller slice of the global market, its per capita biologics spending ranks among the highest in the OECD (Organisation for Economic Co-operation and Development), making it a valuable market for both branded and biosimilar products.

"The launch of NIOPEG as a biosimilar to NEULASTA represents a strategic milestone in our growth trajectory," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. By entering the high value-added biologics market with a cost-effective and clinically equivalent alternative, we are strengthening our portfolio, expanding our addressable market, and creating new revenue streams. This reinforces our commitment to delivering sustainable value to patients, the healthcare system, and our shareholders alike."

About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 72 generic prescription drugs on the market in Canada and more than 12 additional drugs planned to be launched in the remainder of 2025. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, visit www.sunshinebiopharma.com.